DUBLIN--(BUSINESS WIRE)--The "Legionella Testing Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
The global Legionella testing market is experiencing considerable growth due to factors like the rising incidence of pneumonia and Legionella-related illnesses, increasing demand for rapid advanced diagnostic techniques and technological advancements in the field of bacterial testing.
As per the Centers for Disease Control and Prevention (CDC) estimates, the US witnessed 6238 cases of Legionnaires' disease in 2017. While this incidence number is relatively low, it is still an increment of 13.6% in the number of cases when compared to 2016 estimates. Legionnaires' disease is not contagious but the disease can be contracted by contaminated water droplets and mist. Similar to the US, Legionnaires' disease in EU countries is an uncommon and sporadic respiratory infection with low notification rates. According to the European Centre for Disease Prevention and Control (ECDC), the overall notification rate for Legionnaires' disease increased significantly over the 2011-2015 period.
France, Germany, Italy, and Spain accounted for 69% of all the notified cases in 2015. Despite the low overall number of cases of Legionnaires' disease incidence, the high growth rate of its prevalence globally is contributing to the growth of the global Legionella testing market. There has been a significant increase in the prevalence of the Legionnaires' disease globally in the past 5 years. With the rising cases of legionella there is an vital need for the management of disease which can be done by diagnosis and treatment.
Key Market Trends
Urinary Antigen Test (UAT) is Expected to Hold Largest Share of Global Legionella Testing Market, Over the forecast period
By type of test, the global Legionella testing market is dominated by UAT, which holds the largest market share among all variants of the diagnostic test for Legionella testing. UAT is a diagnostic tool which provides rapid outcomes, with usually same-day results. Additionally, UAT is not resource-specific and technically intensive like culture-based tests. Since UAT does not require respiratory fluid samples, issues of sensitivity are also overcome. Overall, UAT remains the test for choice for clinicians and diagnostic experts primarily because of ease of handling and rapid testing advantage.
There is currently limited use of polymerase chain reaction (PCR) based tests and other nucleic acid-based tests in the global Legionella market. However, over the forecast period, this test category is expected to grow significantly because it provides differential advantage like detection of entire serogroups associated with Legionella and rapid testing. Its widespread use in the current market is limited due to the high cost of PCR techniques.
North America Region Holds the Largest Market Share of Legionella Testing Market
North America dominated the market due to the increasing cases of patients suffering from Legionella infections and the presence of key players in this region. Furthermore, In order to manage the prevalence of LD the government of USA (CDC) is increasing the awareness among the general public with the environmental legionella isolation techniques evaluation (ELITE) program which will further augment the growth of the market.
In 2018, the ELITE Program is planning to add additional performance evaluation criteria to its reports. This would allow regional, national, and international accrediting bodies to evaluate the laboratories in a variety of detection methods, including PCR and bacterial enzyme detection.
The Legionella Testing Market consists of several major players. The companies are implementing certain strategic initiatives such as a merger, new product launch, acquisition and partnerships that help them in strengthening their market position.
Key Topics Covered
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Incidence of Pneumonia and Legionella-related Illnesses
4.2.2 Increasing Demand for Rapid and Advanced Diagnostic Techniques
4.2.3 Technological Advancements in the Field of Bacterial Testing
4.3 Market Restraints
4.3.1 Insufficient Disposable Income in Developing and Underdeveloped Countries
4.3.2 Issues in Sensitivity of Diagnostic Tests
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Test Type
5.1.1 Culture Method
5.1.2 Urinary Antigen Test (UAT)
5.1.4 Direct Fluoroscent Antibody (DFA) Test
5.1.5 Polymerase Chain Reaction (PCR)
5.2 By Application
5.2.1 Clinical Testing Method
5.2.2 Environmental Testing Method
5.3 By End-User
5.3.1 Hospital and Clinic
5.3.2 Diagnostic Laboratory
5.4.1 North America
18.104.22.168 Rest of Europe
5.4.3 Asia Pacific
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.4.4 Middle East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle East and Africa
5.4.5 South America
220.127.116.11 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Albagaia Ltd.
6.1.2 Aquacert Ltd.
6.1.3 Becton, Dickinson and Company
6.1.4 BioMerieux S.A.
6.1.5 Idexx Laboratories Inc.
6.1.6 Merck Millipore (Merck KGaA)
6.1.7 Pacific Water Technology
6.1.8 Pall Corporation (Danaher Corporation)
6.1.9 Phigenics LLC
6.1.10 Qiagen N.V.
6.1.11 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/kfhfde